Autolus Therapeutics (NASDAQ:AUTL) Shares Up 13.5% on Analyst Upgrade

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report)'s stock price rose 13.5% during mid-day trading on Monday after Needham & Company LLC raised their price target on the stock from $10.00 to $11.00. Needham & Company LLC currently has a buy rating on the stock. Autolus Therapeutics traded as high as $1.89 and last traded at $1.8950. Approximately 2,745,350 shares were traded during mid-day trading, an increase of 11% from the average daily volume of 2,479,643 shares. The stock had previously closed at $1.67.Get Autolus Therapeutics alerts:Several other analysts have also recently commented on the stock. William Blair reiterated an "outperform" rating on shares of Autolus Therapeutics in a research note on Wednesday, September 24th. Wall Street Zen downgraded shares of Autolus Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Saturday, November 15th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Autolus Therapeutics in a research note on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $8.67.Read Our Latest Report on Autolus TherapeuticsInstitutional Investors Weigh In On Autolus TherapeuticsHedge funds have recently added to or reduced their stakes in the stock. Marex Group plc bought a new position in Autolus Therapeutics during the second quarter valued at about $28,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Autolus Therapeutics during the third quarter worth approximately $46,000. R Squared Ltd acquired a new position in shares of Autolus Therapeutics in the second quarter worth $50,000. Invesco Ltd. raised its stake in shares of Autolus Therapeutics by 53.3% during the 1st quarter. Invesco Ltd. now owns 32,738 shares of the company's stock worth $51,000 after purchasing an additional 11,381 shares in the last quarter. Finally, Delaney Dennis R acquired a new stake in Autolus Therapeutics in the second quarter valued at approximately $55,000. 72.83% of the stock is currently owned by institutional investors. Autolus Therapeutics Trading Up 12.9%The firm has a market cap of $501.67 million, a price-to-earnings ratio of -2.30 and a beta of 2.01. The stock has a fifty day moving average price of $1.48 and a 200 day moving average price of $1.78. Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.07). The business had revenue of $21.19 million for the quarter, compared to analyst estimates of $21.08 million. Autolus Therapeutics had a negative return on equity of 63.76% and a negative net margin of 439.69%. On average, sell-side analysts forecast that Autolus Therapeutics PLC Sponsored ADR will post -0.94 EPS for the current year. Autolus Therapeutics Company Profile (Get Free Report)Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications. The company's leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.Featured StoriesFive stocks we like better than Autolus TherapeuticsDo not delete, read immediatelyHow the Rich RetireINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffHow Long Will $1M Last in Retirement?[No Brainer Gold Play]: “Show me a better investment.”This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Autolus Therapeutics Right Now?Before you consider Autolus Therapeutics, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Autolus Therapeutics wasn't on the list.While Autolus Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here